Biotricity Inc. (Biotricity) today reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth by over eight percent from the previously announced $13 million run rate. In its Corporate Impact Report published last spring, Biotricity described both “better patient outcomes and substantial cost savings” for patients using its devices.

Biotricity reports strong growth for its first quarter fiscal year 2024 and provides financial results and business updates

August 15, 2023

Biotricity Inc. (Biotricity) today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023. The company reported that the Q1-FY24 revenue grew by 46.9% YOY to $3.0 million, continuing to advance toward positive cashflow.

C.R. No. 145236-1

August 2023

Biotricity achieves $14 Million Revenue Run Rate in August 2023

Biotricity reports strong growth for its first quarter fiscal year 2024 and provides financial results and business updates